Use the collections feature with a free QxMD account.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Sign up for a free QxMD account to curate your own collections of articles and to follow collections from peers around the world.

Get Started

Collections Dabigatran

Dabigatran

Follow Collection ＋

JOURNAL ARTICLE

Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

T Baglin, A Hillarp, A Tripodi, I Elalamy, H Buller, W Ageno

Oral direct inhibitors (ODIs) of thrombin and factor Xa are now approved as anticoagulant drugs. The first two drugs to complete phase III clinical trials for thromboprophylaxis in orthopaedic surgery and treatment of patients with atrial fibrillation or venous thromboembolism were dabigatran and rivaroxaban. These small molecules are given at fixed dose with no requirement for monitoring as pharmacokinetic and pharmacodynamic responses are reliably predicted in patients with adequate renal function who are not taking other interacting drugs...

23347120

January 24, 2013: Journal of Thrombosis and Haemostasis: JTH

Make the most of Read.
Download the mobile app.

Use the collections feature with a free QxMD account.

Dabigatran

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips